News

Many features that are specific to glaucoma patients raise concerns about whether they are appropriate candidates for multifocal IOLs. In the absence of extensive clinical data to guide decision-making, the benefits and compromises must be considered carefully in each patient.

IOL effects on contrast sensitivity are a major consideration for selecting implants in patients with glaucoma who are undergoing cataract surgery. On this basis, an aspheric IOL is preferred except in the rare patient with a history of hyperopic LASIK, whereas presbyopia-correcting IOLs are best avoided.

Increasing the funding for the National Eye Institute is one of the goals of non-profit advocacy coalition National Alliance for Eye and Vision Research and its education affiliate, the Alliance for Eye and Vision Research. The organizations, however, do not expect the budget for fiscal year 2009 to be finalized until February, after the presidential election.

Ongoing analysis of data from the Early Manifest Glaucoma Trial (EMGT) has shown that positive cardiovascular history and thinner central corneal thickness increase the risk of progression, but only in patients with higher baseline IOP. Low blood pressure emerged as a risk factor in normal-tension glaucoma.

High blood pressure and high cholesterol may be connected to an increased risk of retinal vein occlusion, according to a study conducted by researchers at the Royal College of Surgeons.

Rockville, MD-The FDA has postponed a review of an investigational prosthetic device for the treatment of age-related macular degeneration (AMD) at the request of its developer, VisionCare Ophthalmic Technologies Inc., so that the company can submit additional long-term clinical data.

Irvine, CA-Preliminary analysis of the second-and-final phase III clinical study of bepotastine ophthalmic solution (Bepreve, ISTA Pharmaceuticals) is encouraging, according to the company.

Buffalo Grove, IL-Akorn Inc. has received FDA approval of its abbreviated new drug applications for 0.1% diclofenac sodium ophthalmic solution and 0.3% ofloxacin ophthalmic solution USP.

Management of thyroid eye diseases should be individualized to the severity of signs and symptoms of each patient and based as well on whether the disease is in an active or quiescent phase. Some corrective procedures should be postponed for months or years until the disease no longer is active.

A retrospective study of eyes with a spherical IOL implanted found the lens haptics maintained a stable position in most eyes, but significant rotation was observed in a small proportion. This information is important to consider when implanting toric IOLs where orientation and rotation can affect vision outcomes.

Posterior keratocyte densities were significantly lower in ectatic eyes than in normal eyes following both histopathologic and confocal microscopic analysis in a recent small study. If further studies verify that finding, serial confocal measurements of density could be used to monitor progression of post-LASIK ectasia.

LASIK and PRK are both safe and, over the long term, produce similar visual outcomes. A preference for one or the other can be based on both scientific evidence and personal opinions, and it is a complex decision that does not necessarily have a right or wrong answer. Physicians should fully inform patients of the pros and cons of both and respect the decision, suggested participants in a point-counterpoint debate.

The Verteporfin Intravitreal Triamcinolone Acetonide Study (VERITAS) of intravitreal triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) or pegaptanib (Macugen, Pfizer) in combination with photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharmaceuticals) was underpowered to reach definitive conclusions about the therapies.

A tear-testing platform under development could revolutionize osmolarity testing by making it possible to conduct tests quickly and accurately in the practice setting using a small volume of tears.

Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) is beneficial for treating patients with dry eye because it increases goblet cell density and production of transforming growth factor ?2, an immunoregulatory factor, compared with artificial tear formulations, which do not.

A hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma) is a preservative-free product recommended for once-daily insertion in the inferior cul-de-sac. Its convenience, efficacy, and safety make it a valuable option for the management of dry eye disease.

When initiating treatment with topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), adjunctive use of loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch & Lomb) hastens and increases relief of dry eye signs and symptoms and reduces cyclosporine-associated burning and stinging without adding safety concerns, according to the results of a multicenter, randomized, controlled, masked trial comparing the combination regimen with cyclosporine plus artificial tears.

Multiple studies evaluating the effects of treatment with Systane Lubricant Eye Drops (Alcon Laboratories) on corneal staining in patients with dry eye disease demonstrate this novel artificial tear has benefits for improving ocular surface health.

Carboxymethylcellulose 0.5% with compatible solutes (CMC-solutes) (Optive, Allergan), a new artificial tear formulation, when used with topical cyclosporine 0.05% (Restasis, Allergan) in patients with ocular surface disease, improved the objective signs and subjective symptoms of the disease when compared with the patients' previously used artificial tears.

A new lubricating eye drop (blink Tears, Advanced Medical Optics) with the active ingredient polyethylene glycol is designed to provide a balance between viscosity and retention without sacrificing a patient's visual quality. It can help optimize the ocular surface before and after refractive surgery, aiding postoperative visual outcomes and patient satisfaction.

A cerium oxide nanoparticle bound to a human carbonic anhydrase inhibitor (hCAII) has shown promise as a drug-delivery device for treating glaucoma. In a series of experiments, investigators attached hCAII to the nanoparticle and also attached a fluorophore so that they could confirm the attachment and track the particle's inhibitory effects.

The tornado that hit March 14 in downtown Atlanta is not expected to affect plans for the joint meeting of the American Academy of Ophthalmology (AAO) and the European Society of Ophthalmology in November, according to the AAO.

The first World Glaucoma Day was held March 6. The World Glaucoma Association (WGA) and the World Glaucoma Patient Organization (WGPA) sponsored the observance. The Ophthalmology Times Group was the official news source of the event, providing e-newsletter coverage of the awareness and educational activities organized by glaucoma institutions and local patient support groups worldwide.

Cerimon Pharmaceuticals has entered into an agreement with Novartis Pharma AG to conduct a proof-of-concept study of basiliximab (Simulect) for the treatment of noninfectious uveitis.

Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.

Facial rejuvenation procedures can be worthwhile adjuncts to an ophthalmology practice. Surgeons, however, require detailed knowledge of products and anatomy, must make patient education a priority, and should obtain specific training. Patients undergoing cosmetic procedures often have very high expectations, and it is important to have an in-depth understanding of aesthetic facial anatomy and features.

As the Asian eye-care market begins to explode, Alcon Inc. is preparing to be close to the action by adding a manufacturing plant in Singapore. The 250,000-square-foot plant, which will employ 150 people, will manufacture pharmaceuticals to be distributed throughout Asia, with the exception of Japan.

Prevent Blindness has dedicated May as UV Awareness Month in an effort to educate the public on the best way to protect their eyes.